Atlas Venture Amends Disc Medicine Stake, Signals Ownership Change

TL;DR

**Atlas Venture is selling some Disc Medicine shares, watch for potential stock movement.**

AI Summary

Atlas Venture, a significant shareholder in Disc Medicine, Inc., filed an amendment to its Schedule 13D on January 23, 2024. This filing indicates a change in their beneficial ownership, specifically a decrease in their holdings of Disc Medicine's Common Stock, $0.0001 par value per share. While the exact number of shares sold isn't detailed in this snippet, the amendment suggests a reduction in their stake, which could signal a shift in Atlas Venture's investment strategy or a move to realize gains. For current or prospective shareholders, this matters because a major institutional investor reducing its position can sometimes be interpreted as a lack of confidence in the company's near-term prospects or a rebalancing of their portfolio.

Why It Matters

A major institutional investor, Atlas Venture, has adjusted its holdings in Disc Medicine, which could influence market perception and potentially impact the stock price.

Risk Assessment

Risk Level: medium — A significant investor reducing its stake can create selling pressure or signal concerns, introducing moderate risk for other shareholders.

Analyst Insight

Investors should monitor subsequent filings from Atlas Venture to understand the extent of their ownership changes and consider the potential impact on Disc Medicine's stock price, especially if the selling continues.

Key Players & Entities

• Atlas Venture (company) — filing person and significant shareholder of Disc Medicine, Inc.
• Disc Medicine, Inc. (company) — subject company whose securities are being reported
• Ommer Chohan (person) — Chief Financial Officer of Atlas Venture, authorized to receive notices
• $0.0001 (dollar_amount) — par value per share of Disc Medicine's Common Stock
• January 23, 2024 (date) — date of the event requiring the filing of this statement

Forward-Looking Statements

• Atlas Venture will continue to adjust its holdings in Disc Medicine, potentially further reducing its stake. (Atlas Venture) — medium confidence, target: Q1 2024

FAQ

Key Financial Figures

• $0.0001 — INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class o

Filing Documents

• tm244152d1_sc13da.htm (SC 13D/A) — 228KB
• 0001104659-24-006716.txt ( ) — 231KB

INTEREST IN SECURITIES OF THE ISSUER

ITEM 5. INTEREST IN SECURITIES OF THE ISSUER

of the Prior Schedule 13D is hereby amended

Item 5 of the Prior Schedule 13D is hereby amended and restated as follows; (a)(b) As of the date hereof, Atlas X is the record owner of 1,402,186 shares of Common Stock. AVA X LP is the general partner of Atlas X and AVA X LLC is the general partner of AVA X LP. Each of Atlas X, AVA X LP and AVA X LLC has shared voting and dispositive power over the shares held by Atlas X. As such, each of Atlas X, AVA X LP and AVA X LLC may be deemed to beneficially own the shares held by Atlas X. As of the date hereof, Atlas XII is the record owner of 51,000 shares of Common Stock. AVA XII LP is the general partner of Atlas XII and AVA XII LLC is the general partner of AVA XII LP. Each of Atlas XII, AVA XII LP and AVA XII LLC has shared voting and dispositive power over the shares held by Atlas XII. As such, each of Atlas XII, AVA XII LP and AVA XII LLC may be deemed to beneficially own the shares held by Atlas XII. As of the date hereof, AVOF is the record AVOF, AVAO LP and AVAO LLC has shared voting and dispositive power over the shares held by AVOF. As such, each of AVOF, AVAO LP and AVAO LLC may be deemed to beneficially own the shares held by AVOF. As of the date hereof, AVOF II is the record owner of 198,326 shares of Common Stock. AVAO II LP is the general partner of AVOF II and AVAO II LLC is the general partner of AVAO II LP. Each of AVOF II, AVAO II LP and AVAO II LLC has shared voting and dispositive power

View Full Filing

View this SC 13D/A filing on SEC EDGAR